
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024
Description
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024
DelveInsight’s, Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Oncolytic Virus Cancer Therapy: Overview
Oncolytic virotherapy is a treatment of using a virus that can replicate itself to kill cancer cells. There are many species of viruses, but not all of them can be designed to be an oncolytic virus (OV). The typical features of these OVs must include being non-pathogenic, the ability to target and kill the cancer cells, and the capacity of being transformed to express tumor-killing factors through genetic engineering methods. Tumor selectivity could be concerned with the level of receptor-mediated cell entry, intracellular antiviral responses, or restriction factors that determine the susceptibility of the infected cell that leads to viral gene expression and replication.
""Oncolytic Virus Cancer Therapy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oncolytic Virus Cancer Therapy pipeline landscape is provided which includes the disease overview and Oncolytic Virus Cancer Therapy treatment guidelines. The assessment part of the report embraces, in depth Oncolytic Virus Cancer Therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncolytic Virus Cancer Therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches to treat/improve Oncolytic Virus Cancer Therapy.
- In February 2022, Synthetic Biologics announced that VCN Biosciences, VCN-01 received Orphan Drug Designation for retinoblastoma from the US Food & Drug Administration (FDA).
- In March 2022, Synthetic Biologics announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.
- In September 2021, CG Oncology announced a clinical trial collaboration to evaluate the safety and efficacy of CG0070, an oncolytic immunotherapy, in combination with OPDIVO (nivolumab), Bristol Myers Squibb’s anti-PD-1 therapy, for the treatment of metastatic urothelial cancer in a Phase I/II clinical study.
- In March 2021, Orgenesis Inc. announced that it has entered the planned second phase of a collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The collaboration is focused on an exclusive license agreement to further develop and commercialize the hospital’s proprietary Celyvir therapy for the treatment of solid tumors.
- Olvi-Vec: Genelux Corporation
- CAN-2409: Candel Therapeutics
- CG0070: CG Oncology
- Pelareorep: Oncolytics Biotech
- ParvOryx: Oryx GmbH
- SND005: Jiangsu Sinorda Biomedicine
- VCN-01: VCN Biosciences
Further product details are provided in the report……..
Oncolytic Virus Cancer Therapy: Therapeutic Assessment
This segment of the report provides insights about the Oncolytic Virus Cancer Therapy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Oncolytic Virus Cancer Therapy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intranasal
- Intravenous
- Oral
- Oral/Intravenous
- Parenteral
- Subcutaneous
- Subcutaneous/Intramuscular
- Molecule Type
- Oncolytic Viruse
- Product Type
Oncolytic Virus Cancer Therapy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.
Oncolytic Virus Cancer Therapy Report Insights
- Oncolytic Virus Cancer Therapy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Oncolytic Virus Cancer Therapy drugs?
- How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oncolytic Virus Cancer Therapy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Genelux Corporation
- Candel Therapeutics
- CG Oncolgy
- DNAtrix
- SillaJen Biotherapeutics
- Oncolytics Biotech
- Wuhan Binhui Biotechnology
- Oryx GmbH
- Jiangsu Sinorda Biomedicine Co., Ltd
- Elicera Therapeutics
- Orgenesis
- Replimune
- Immvira Pharma
- ViroCure
- GeneMedicine
- PsiOxus Therapeutics
- PsiOxus Therapeutics
- Vyriad
- VCN Biosciences
- Beijing Syngentech
- GeneMedicine
- GeneMedicine
- GeneMedicine
- Oncolys BioPharma
- SillaJen Biotherapeutics
- Turnstone Biologics
- Olvi-Vec
- CAN-2409
- CG0070
- DNX-2401
- Pexa-Vec
- Pelareorep
- OH 2
- ParvOryx
- SND005
- ELC-100
- AloCelyvir
- RP2
- MVR-C5252
- RC402
- GM 101
- NG-641
- NG-350A
- MV-NIS
- VCN-01
- SynOV 1.3
- GM103
- GM102
- GM104
- OBP-702
- JX-970
- RIVAL-02
Table of Contents
280 Pages
- Introduction
- Executive Summary
- Oncolytic Virus Cancer Therapy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Oncolytic Virus Cancer Therapy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Olvi-Vec: Genelux Corporation
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SND005: Jiangsu Sinorda Biomedicine
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- AloCelyvir: Orgenesis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- VCN-01: VCN Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- SynOV 1.3: Beijing Syngentech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Oncolytic Virus Cancer Therapy Key Companies
- Oncolytic Virus Cancer Therapy Key Products
- Oncolytic Virus Cancer Therapy- Unmet Needs
- Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
- Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
- Oncolytic Virus Cancer Therapy Analyst Views
- Oncolytic Virus Cancer Therapy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.